OXYCODONE KALCEKS SOLUTION FOR INJECTION OR INFUSION 10 MG/ML

GOLDPLUS UNIVERSAL PTE LTD

GOLDPLUS UNIVERSAL PTE LTD

Therapeutic

Prescription Only

INJECTION, SOLUTION

**4.2 Posology and method of administration** Posology The dose should be adjusted according to the severity of pain, the total condition of the patient and previous or concurrent medication. _Adults over 18 years:_ The following starting doses are recommended. A gradual increase in dose may be required if analgesia is inadequate or if pain severity increases. IV (Bolus): Dilute to 1 mg/ml in sodium chloride 9 mg/ml (0.9%) solution for injection, 50 mg/ml (5%) dextrose or water for injections. Administer a bolus dose of 1 to 10 mg slowly over 1–2 minutes. Doses should not be administered more frequently than every 4 hours. IV (Infusion): Dilute to 1 mg/ml in sodium chloride 9 mg/ml (0.9%) solution for injection, 50 mg/ml (5%) dextrose or water for injections. A starting dose of 2 mg/hour is recommended. IV (PCA): Dilute to 1 mg/ml in sodium chloride 9 mg/ml (0.9%) solution for injection, 50 mg/ml (5%) dextrose or water for injections. Bolus doses of 0.03 mg/kg should be administered with a minimum lock-out time of 5 minutes. SC (Bolus): Use as 10 mg/ml concentration. A starting dose of 5 mg is recommended, repeated at 4-hourly intervals as required. SC (Infusion): Dilute in sodium chloride 9 mg/ml (0.9%) solution for injection, 50 mg/ml (5%) dextrose or water for injections if required. A starting dose of 7.5 mg/day is recommended in opioid naïve patients, titrating gradually according to symptom control. Cancer patients transferring from oral oxycodone may require much higher doses (see below). _Transferring patients between oral and parenteral oxycodone:_ The dose should be based on the following ratio: 2 mg of oral oxycodone is equivalent to 1 mg of parenteral oxycodone. It must be emphasised that this is a guide to the dose required. Inter-patient variability requires that each patient is carefully titrated to the appropriate dose. The patient should be monitored closely until stable when switching opioid medications. _Elderly patients:_ Elderly patients should be treated with caution. The lowest dose should be administered with careful titration to pain control. _Patients with renal and hepatic impairment:_ The dose initiation should follow a conservative approach in these patients. The recommended adult starting dose should be reduced by 50% (for example a total daily dose of 10 mg orally in opioid naïve patients), and each patient should be titrated to adequate pain control according to their clinical situation (see section 5.2 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). _Paediatric population:_ There are no data on the use of oxycodone injection in patients under 18 years of age. _Use in non-malignant pain:_ Opioids are not first-line therapy for chronic non-malignant pain, nor are they recommended as the only treatment. Types of chronic pain which have been shown to be alleviated by strong opioids include chronic osteoarthritic pain and intervertebral disc disease. The need for continued treatment in non-malignant pain should be assessed at regular intervals. _Duration of treatment:_ Oxycodone should not be used for longer than necessary. _Discontinuation of treatment:_ When a patient no longer requires therapy with oxycodone, it may be advisable to taper the dose gradually to prevent symptoms of withdrawal. For instructions on dilution of the medicinal product before administration, see section 6.7 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_. Method of administration Subcutaneous injection or infusion. Intravenous injection or infusion.